Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on February 21, 2008
Japanese Journal of Clinical Oncology 2008 38(3):230-232; doi:10.1093/jjco/hym174
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/3/230    most recent
hym174v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ohyashiki, K.
Right arrow Articles by Ohyashiki, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohyashiki, K.
Right arrow Articles by Ohyashiki, J. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Isolated Erythrocythemia: A Distinct Entity or a Sub-type of Polycythemia Vera?

Kazuma Ohyashiki, Toru Kiguchi, Yoshikazu Ito, Akihiko Gotoh, Tetsuzo Tauchi, Keisuke Miyazawa and Yukihiko Kimura

The First Department of Internal Medicine
(Hematology Division)
Tokyo Medical University
6-7-1 Nishi-shinjuku, Shinjuku-ku
Tokyo 160-0023, Japan
E-mail: ohyashik@rr.iij4u.or.jp

Hisashi Hisatomi

Department of Material and Life Science
Seikei University, Japan

Junko H. Ohyashiki

Intractable Immune Disease Research Center
Tokyo Medical University
Japan

The first 10% of the full text of this article appears below.

To the Editor:

Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic disorders encompassing chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia and chronic idiopathic myelofibrosis. Since the hematological features of CMPD patients overlap with each other, it is proposed that a common biological mechanism may be present in CMPD. In 2001, the WHO classification proposed CMPD as a disease related to constitutive up-regulation of tyrosine kinase activity (1). More recently, the revised WHO-2008 reclassified CMPD as a subset of myeloproliferative neoplasms derived from hematopoietic stem cells (2). Five papers regarding up-regulation of Janus activating kinase-2 (JAK2) in CMPD appeared in 2005 (3–7): the JAK2 617V > F mutation occurs in the vast majority of patients with PV and ~30% of PV patients exhibit homozygous mutation as a result of uniparental disomy. In 2007, Scott et . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?